Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Literature
1.
2.
Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658–67.CrossRef
3.
Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73.CrossRef
4.
Ghidini M, Tomasello G, Botticelli A, Barni S, Zabbialini G, Seghezzi S, et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB (Oxford). 2017;19(9):741–8.CrossRef
5.
Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015–27.CrossRef
6.
Ma WJ, Jin YW, Wu ZR, Yang Q, Wang JK, Liu F, et al. Meta-analysis of randomized clinical trials of adjuvant chemotherapy for resected biliary tract cancers. HPB (Oxford). 2020;22(7):939–49.CrossRef
Metadata
Title
Reply to “Comment on: Adjuvant Chemotherapy in Resectable Gallbladder Cancer is Underutilized Despite Benefits in Node-Positive Patients”
Authors
Phillip M. Kemp Bohan, MD
Daniel W. Nelson, DO
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09170-6

Other articles of this Special Issue 3/2020

Annals of Surgical Oncology 3/2020 Go to the issue

ASO Author Reflections

ASO Author Reflections: Avoiding Mastectomy: The Benefit of Neoadjuvant Chemotherapy for Large Unifocal Breast Tumors

ASO Author Reflections

ASO Author Reflections: Is Sentinel Lymph Node Biopsy Necessary in Patients with Ductal Carcinoma In Situ with Microinvasion Diagnosed on Core Biopsy?

ASO Author Reflections

ASO Author Reflections: The Beneficial Effect of High-Volume Center Experience on Surgical Outcomes After Total Pancreatectomy

ASO Author Reflections

ASO Author Reflection: Postoperative Chemotherapy for Nonmetastatic, Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas

ASO Author Reflections

ASO Author Reflections: Lymph Node Metastasis in Pancreatic Neuroendocrine Tumor

Correction

Correction to: Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma